医药企业的竞争优势塑造与战略选择研究  

Research on Competitive Advantage Cultivation and Strategic Choice of Pharmaceutical Enterprises

作　　者：杨建华[1] 杨德锋[1] 

机构地区：[1]暨南大学管理学院,广东广州510632

出　　处：《科技管理研究》2010年第18期14-16,24,共4页Science and Technology Management Research

基　　金：教育部人文社会科学研究项目"零售商自有品牌购买行为与商店忠诚例U型关系的形成原因:基于顾客体验视角的研究"(09YJC630100);中央高校基本科研业务费专项资金"品牌体验对品牌至爱的影响"(10JYB2045);暨南大学"211工程"三期建设项目"服务运营与品牌管理"

摘　　要：与跨国公司相比,国内企业存在着研发水平不足、规模实力较小等问题。对于这些问题的解决,医药各子行业中的企业在总体战略上有着各自的选择方向,如:原料药企业的战略选择是通过购并等扩大规模,取得规模优势,以及加速产品仿制和开发;化学制剂药企业是模仿性创新;中药企业是在国内市场塑造知名企业品牌或者产品品牌,在国际市场推动中药规范化;生物制药企业是购买专利和加大研发投入。Compared to the international pharmaceutical enterprises,domestic companies are smaller in the level of research and development.For these problems,domestic companies in different pharmaceutical industries have different choice in their strategy.Active pharmaceutical ingredients companies should get scale advantage through purchasing,and accelerate drag copy and development.Chemical agent companies should develop imitated innovation.Chinese traditional medicine companies should develop company brand or product brand in domestic market,and promote standardization of Chinese traditional medicine in oversea market.Biologic companies should purchase patents and increase investment of research and development.

关 键 词：医药企业 竞争优势 战略选择 规模优势 

分 类 号：F426.72[经济管理—产业经济]